Navigation Links
Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
Date:6/8/2017

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.

SBI-101 is a combination product that combines mesenchymal stromal cells (MSCs) within a blood-filtration device, allowing for controlled, dynamic interaction of MSCs with a patient’s bloodstream. SBI-101 offers two major advantages over traditional, intravenous cell therapy: (1) The duration of cell therapeutic bioactivity is significantly extended by maintaining the MSCs outside the body, in an extracorporeal device; and (2) the MSC cell dose can be increased beyond intravenous limits because the cells are immobilized in the device.

To treat AKI, SBI-101 integrates seamlessly into a continuous renal replacement therapy (CRRT) circuit, thereby providing patients with both standard-of-care and MSC-mediated blood conditioning in a single session.

“Moving our lead product into the clinic marks a major milestone for our company,” said Sentien CEO, Brian Miller. “We look forward to working with our clinical sites to advance development of SBI-101 for this significant unmet medical need.”

The multi-center trial is a randomized, controlled Phase 1/2 study in patients with AKI receiving CRRT. The primary objective of the trial is to evaluate the safety and tolerability of SBI-101 in patients with AKI. Endpoints for efficacy and pharmacodynamic responses to SBI-101 therapy will also be evaluated. Patient recruitment is expected to continue into 2018, with an estimated enrollment of 24 patients.

Please visit http://www.clinicaltrials.gov/show/NCT03015623 for more information about the study.

About Acute Kidney Injury:

Acute kidney injury is a sudden loss of kidney function, caused by conditions such as sepsis, heart surgery, or trauma. Patients diagnosed with severe AKI are placed on dialysis, require extensive stays in the ICU, and are at higher risk of progressing to chronic kidney disease, end-stage renal disease, or death.

About Sentien Biotechnologies:

Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company pioneering new approaches to cell therapy. Sentien’s technology harnesses the power of cell therapy with innovative drug delivery systems to treat a wide range of systemic inflammatory diseases. Sentien’s lead product, SBI-101, is designed to allow for controlled, sustained delivery of mesenchymal stromal cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic factors that are unattainable by direct injection.

SBI-101 is the first product application of Sentien’s platform blood-conditioning technology that has the potential to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.

For more information, please visit http://www.sentienbiotech.com.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14402977.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Portage Invests in Sentien Biotechnologies Inc.
2. CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avalanche Biotechnologies, Inc. - AAVL
4. Harwood Feffer LLP Announces Investigation of Avalanche Biotechnologies, Inc.
5. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc.
6. AVALANCHE BIOTECHNOLOGIES, INC. SHAREHOLDER UPDATE: Kessler Topaz Meltzer & Check, LLP Announces Update to Shareholder Class Action Against Avalanche Biotechnologies, Inc. -- AAVL
7. Base Pair Biotechnologies, Inc. and Nexmos, Inc. Create the First DNA Aptamers that Inhibit Vitamin C Oxidation
8. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
9. Annual Conference about Technology Solutions for People with Disabilities Announces Program
10. Probiotic Action Announces Probiotics Lead the Digestive Health Market
11. Verenium Announces Preliminary Financial Results For Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... 2017  Kibow Biotech Inc., a pioneer in developing ... of a new patent covering a unique method for ... Patent and Trademark Office on May 23 rd ... of Bio award in 2014 in San ... approaches to chronic disease. Renadyl™, the first and only ...
(Date:6/19/2017)... NJ (PRWEB) , ... June 19, 2017 , ... ... for overseeing all service activities supporting EDETEK’s products including training, implementation, support, and ... experience to his new role. He has previously held leadership roles for service ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation ... announced two more sessions of its “From the Helm” Webinar Series. , ... of online templates for design control exercises. Led by David Cronin, Cognition’s CEO, ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... secured a Series B round of financing in the amount of $6 million. ... private investors participated in the round. , The Series B funding will enable ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):